The Top Line Patent expirations push biopharma industry toward a tougher 2026
14 snips
Mar 13, 2026 Kevin Dunleavy, a pharma journalist and analyst at Fierce Pharma, breaks down Q4 2025 results and what they signal for 2026. He highlights widespread conservative guidance, looming patent cliffs and losses of exclusivity, surprising sales declines like Novo Nordisk's, and the intensifying GLP-1 rivalry between Eli Lilly and Novo Nordisk.
AI Snips
Chapters
Transcript
Episode notes
Industry Wide Guidance Tilting Conservative
- Many top 25 biopharma companies are guiding to slower growth for 2026.
- Kevin Dunleavy links this conservatism to uncertainty and emerging patent cliffs rather than uniform policy impacts.
Novo Nordisk's Surprise Downshift
- Novo Nordisk shocked analysts by projecting a 5%–13% sales decline for 2026 after 5% growth in 2025.
- The company cited unprecedented pricing pressures and a most-favored-nation pricing deal as drivers of the conservative outlook.
Patent Cliff Pain Drives Guidance
- Many companies' weaker guidance stems from micro effects like losses of exclusivity rather than broad policy shocks.
- Kevin Dunleavy notes the decade-long wave of patent cliffs is starting to hit and shape 2026 outlooks.